Tag
Review of recent studies highlights venetoclax plus azacitidine as a feasible and effective therapy in younger AML patients, challenging standard intensive chemotherapy paradigms and suggesting a shift toward lower-intensity regimens with c
The INTERVENE trial reveals that adding midostaurin to low-dose cytarabine and venetoclax is tolerable and improves FLT3-ITD clearance and survival in older AML patients with FLT3-ITD, addressing resistance in this high-risk subgroup.
Telomere length serves as an independent prognostic marker for progression-free survival in chronic lymphocytic leukemia patients treated with venetoclax-based regimens, highlighting its role in risk stratification during the modern targete
This article reviews the KOMET-007 trial evaluating ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated AML, highlighting promising remission rates and manageable safety.
This review synthesizes evidence from the ELEVATE trial on adding cusatuzumab, a CD70-targeting antibody, to venetoclax with or without azacitidine in unfit AML patients, highlighting therapeutic potential, safety concerns, and translationa
The GLOW phase III trial demonstrates that fixed-duration ibrutinib-venetoclax provides superior overall survival, progression-free survival, and safety compared to chlorambucil-obinutuzumab in older/comorbid CLL patients, with durable dise
A phase 1 trial demonstrates that venetoclax combined with inotuzumab ozogamicin is safe and highly effective in producing durable MRD-negative remissions in relapsed/refractory B-cell ALL and lymphoblastic lymphoma.
A phase 2 trial demonstrates that adding venetoclax to pediatric chemotherapy regimens in adolescents and adults with newly diagnosed Philadelphia chromosome-negative ALL significantly improves MRD negativity and survival with manageable to
This review synthesizes cutting-edge findings on how genetic and nongenetic RAS-pathway activation mediates resistance to combined FLT3 and BCL2 inhibition in acute myeloid leukemia, highlighting implications for treatment strategies and bi
The phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid ma
This study analyzes outcomes of azacitidine versus decitabine, with or without venetoclax, in TP53-mutant AML, revealing comparable survival outcomes and highlighting the independent prognostic impact of multi-hit TP53 status.
The phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensive
Chromosome 5q deletions combined with TP53 mutations drive stepwise aneuploid evolution in complex karyotype AML, unveiling shared transcriptional vulnerabilities exploitable by targeted therapies like BCL2 inhibition with venetoclax.
A multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognostica
A retrospective study delineates relapse risks and survival outcomes in adult acute myeloid leukemia patients who achieve first complete remission without undergoing allogeneic stem cell transplantation, highlighting venetoclax’s role in re
In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA reg
Oral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particula
BRAF mutations occur in about 1% of AML and are usually non-V600 variants enriched in myelodysplasia-related disease. This cohort study found poor survival and suggested that current therapies, including venetoclax-based regimens, remain in
A newly developed prognostic model integrates mutational and cytogenetic data to accurately predict survival in AML patients receiving HMA/VEN therapy, offering superior risk stratification into low-, intermediate-, and high-risk categories
The Phase III CANOVA trial evaluated venetoclax-dexamethasone against pomalidomide-dexamethasone in t(11;14)-positive RRMM. While the primary endpoint of progression-free survival was not statistically met, the study revealed significant im
